机构：[1]Cleveland Clinic, Cleveland, Ohio, New York, USA[2]Memorial Sloan-Kettering Cancer Center, New York, New York, USA[3]Mayo Clinic, Rochester, Minnesota, New York, USA[4]Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China河北医科大学第四医院[5]Oregon Health and Science University, Portland, Oregon, New York, USA[6]Indiana University, Indianapolis, Indiana, New York, USA[7]Queen Mary Hospital, University of Hong Kong Medical Center, Hong Kong, China[8]University Hospital Leuven, Leuven, Belgium[9]Medical University of South Carolina, Charleston, South Carolina, New York, USA[10]Helsinki University Hospital, Helsinki, Finland[11]Fox Chase Cancer Center, Philadelphia, Pennsylvania, New York, USA[12]University of Texas MD Anderson Cancer Center, Houston, Texas, New York, USA[13]University of Rochester, Rochester, New York, USA
The aim of this study is to report assemblage of a large multi-institutional international database of esophageal cancer patients, patient and tumor characteristics, and survival of patients undergoing esophagectomy alone and its correlates. Forty-eight institutions were approached and agreed to participate in a worldwide esophageal cancer collaboration (WECC), and 13 (Asia, 2; Europe, 2; North America, 9) submitted data as of July 1, 2007. These were used to construct a de-identified database of 7884 esophageal cancer patients who underwent esophagectomy. Four thousand six hundred and twenty-seven esophagectomy patients had no induction or adjuvant therapy. Mean age was 62 +/- 11 years, 77% were men, and 33% were Asian. Mean tumor length was 3.3 +/- 2.5 cm, and esophageal location was upper in 4.1%, middle in 27%, and lower in 69%. Histopathologic cell type was adenocarcinoma in 60% and squamous cell in 40%. Histologic grade was G1 in 32%, G2 in 33%, G3 in 35%, and G4 in 0.18%. pT classification was pTis in 7.3%, pT1 in 23%, pT2 in 16%, pT3 in 51%, and pT4 in 3.3%. pN classification was pN0 in 56% and pN1 in 44%. The number of lymph nodes positive for cancer was 1 in 12%, 2 in 8%, 3 in 5%, and > 3 in 18%. Resection was R0 in 87%, R1 in 11%, and R2 in 3%. Overall survival was 78, 42, and 31% at 1, 5, and 10 years, respectively. Unlike single-institution studies, in this worldwide collaboration, survival progressively decreases and is distinctively stratified by all variables except region of the world. A worldwide esophageal cancer database has been assembled that overcomes problems of rarity of this cancer. It reveals that survival progressively (monotonically) decreased and was distinctively stratified by all variables except region of the world. Thus, it forms the basis for data-driven esophageal cancer staging. More centers are needed and encouraged to join WECC.
基金：
Daniel and Karen Lee Endowed Chair in Thoracic Surgery; Cleveland Clinic Foundation
第一作者机构：[1]Cleveland Clinic, Cleveland, Ohio, New York, USA[*1]Cleveland Clinic, Department of Thoracic and Cardiovascular Surgery, 9500 Euclid Avenue/Desk J4-1, Cleveland, Ohio 44195, USA
通讯作者：
通讯机构：[1]Cleveland Clinic, Cleveland, Ohio, New York, USA[*1]Cleveland Clinic, Department of Thoracic and Cardiovascular Surgery, 9500 Euclid Avenue/Desk J4-1, Cleveland, Ohio 44195, USA
推荐引用方式(GB/T 7714)：
Rice T. W.,Rusch V. W.,Apperson-Hansen C.,et al.Worldwide esophageal cancer collaboration[J].DISEASES OF THE ESOPHAGUS.2009,22(1):1-8.doi:10.1111/j.1442-2050.2008.00901.x.
APA：
Rice, T. W.,Rusch, V. W.,Apperson-Hansen, C.,Allen, M. S.,Chen, L.-Q....&Blackstone, E. H..(2009).Worldwide esophageal cancer collaboration.DISEASES OF THE ESOPHAGUS,22,(1)
MLA：
Rice, T. W.,et al."Worldwide esophageal cancer collaboration".DISEASES OF THE ESOPHAGUS 22..1(2009):1-8
